INCY Add to watchlist
$97.10 0.59 (-0.60%)
After Hours: $97.10 +0.00 (+0.00%)
Last updated: Apr 15, 2026 21:18
52-Week Range
$97.10
$56.13 $97.10 $112.29

Fundamentals Overview

Incyte Corporation is in the middle of its 52-week range with attractive valuation, trading relatively flat today.

Valuation attractive

P/E 15.5 PEG 0 P/B 3.71 P/S 3.76

Intrinsic value (DCF)

+27% upside vs price

Profitability

Net margin 25%

Risk (Beta)

0.86 — in line vol

Earnings & growth

EPS $6.28 Rev +10.3% Profit -29.4% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 61% confidence Risk: Moderate Volatility — Beta 0.86. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +27% upside vs price · Analyst grade: A

Pressures (Sell):

3M vs S&P 500: -9.4%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$19.32B
P/E (TTM)
15.45
EPS (TTM)
$6.28
Dividend Yield
N/A
52-Week Range
$56.13 - $112.29
Volume vs Avg
N/A
Beta
0.86

About

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome ...
Sector: Healthcare
Headquarters: US
Employees: 2,617
IPO Date: Nov 1993
Beta: 0.86 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: A. Recent institutional grades: mixed. Current institutional positions: Buy: 8, Equal Weight: 4, Hold: 2, In Line: 1, Neutral: 3, Outperform: 1, Overweight: 8, Sector Perform: 3.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $123.29; current price is $97.10. That’s a +27% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 15.45
DCF value (model) $123.29 (27% upside)
PEG (TTM) 0
P/B (TTM) 3.71
P/S (TTM) 3.76
P/FCF (TTM) 14.27
Liquidity & enterprise
Current Ratio (TTM) 3.32
Quick Ratio (TTM) 3.25
Cash Ratio (TTM) 2.04
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 25.03%
Gross margin (TTM) 91.8%
Operating margin (TTM) 26.35%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for INCY.

Analyst Sentiment at a Glance

A Sentiment Mixed
Buy 8Equal Weight 4Hold 2In Line 1Neutral 3Outperform 1Overweight 8Sector Perform 3
2 upgrades, 2 downgrades
Price Target Consensus
Current $97.10
Median $108.50
Consensus $108.90
Low consensus $84.00
High consensus $135.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
HC Wainwright & Co. maintain Buy Buy 2026-03-30
HC Wainwright & Co. maintain Buy Buy 2026-03-25
UBS maintain Neutral Neutral 2026-03-25
Jefferies downgrade Buy Hold 2026-03-16
HC Wainwright & Co. maintain Buy Buy 2026-03-09
Evercore ISI Group maintain In Line In Line 2026-03-05
Barclays maintain Overweight Overweight 2026-02-18
HC Wainwright & Co. maintain Buy Buy 2026-02-11
RBC Capital maintain Sector Perform Sector Perform 2026-02-11
Stifel maintain Buy Buy 2026-02-11
Wells Fargo maintain Equal Weight Equal Weight 2026-02-11
Piper Sandler maintain Overweight Overweight 2026-02-06
Barclays maintain Overweight Overweight 2026-02-04
Wells Fargo downgrade Overweight Equal Weight 2026-01-20
TD Cowen maintain Buy Buy 2026-01-13
Morgan Stanley maintain Equal Weight Equal Weight 2026-01-06
Wells Fargo maintain Overweight Overweight 2025-12-08
Mizuho upgrade Neutral Outperform 2025-12-08
Morgan Stanley maintain Equal Weight Equal Weight 2025-12-08
Barclays maintain Overweight Overweight 2025-11-24
Piper Sandler maintain Overweight Overweight 2025-11-04
Guggenheim upgrade Neutral Buy 2025-11-03
Barclays maintain Overweight Overweight 2025-10-29
Truist Securities maintain Hold Hold 2025-10-29
Wells Fargo maintain Overweight Overweight 2025-10-29
RBC Capital maintain Sector Perform Sector Perform 2025-10-29
JP Morgan maintain Neutral Neutral 2025-10-09
RBC Capital maintain Sector Perform Sector Perform 2025-09-24
Stifel maintain Buy Buy 2025-09-22
Guggenheim maintain Neutral Neutral 2025-09-19